According to recent foreign media reports, Science Corporation announced that its oversubscribed $230 million Series C funding round has ended.

According to Science Corporation, participants in this funding round include Lightspeed Venture Partners, Khosla Ventures, Y Combinator, IQT, and Quiet Capital. The funds will be used to accelerate the commercialization of its brain-computer interface technology. To date, the company has raised approximately $490 million in total funding .

Science Corporation, founded in 2021 and headquartered in Alameda, California, is led by Neuralink co-founder Max Hordak and is currently advancing clinical trials of the Prima retinal implant .

It's worth mentioning that Science possesses the Prima retinal implantation technology developed by Pixium Vision. The Prima system, a photovoltaic alternative to photoreceptor cells, has received Breakthrough Device designation from the U.S. Food and Drug Administration , allowing for the simultaneous use of central prosthetic vision and peripheral natural vision.

Furthermore, Prima technology can restore vision by directly stimulating the retina when rod and cone cells are lost. The system consists of a small photodynamic implant placed under the retina and a pair of specially designed glasses. These glasses have a built-in camera and infrared projector that send light signals to the implant, providing it with power and data.

Currently, Science has submitted marketing applications for Prima to regulatory agencies in the United States and Europe in June, and in October 2025, the company reported positive results for Prima implant users.

According to foreign media reports, Science is expected to become the first brain-computer interface company to commercially available vision restoration products, with plans to launch its products in Europe this year . The company stated that strong investor demand, coupled with several upcoming milestones, facilitated this Series C funding round.

The company also plans to use the funding to support the development of its biohybrid neural interface technology and the Vessel perfusion system . Its biohybrid architecture aims to achieve connectivity with the brain while avoiding the potential damage and limitations of inserting wires into the brain. The Vessel platform represents a reimagining of how extracorporeal membrane oxygenation (ECMO) works.

In addition, Science has expanded its PRIMA clinical trial program to evaluate its efficacy against other retinal diseases, including Staggart's disease and retinitis pigmentosa, both of which can cause retinal vision loss in young people due to genetic factors.

Meanwhile, the company is awaiting CE marking certification in Europe and approval from the U.S. Food and Drug Administration. Its product is expected to be the first commercially available brain-computer interface for vision restoration , while Neuralink, the brain-computer interface company previously founded by Hodak, is also developing a vision restoration implant.

It is worth mentioning that the BCI field is currently very popular. In addition to foreign companies such as Precision, Neuralink, and Synchron accelerating their development, the domestic BCI field is also booming.

In terms of policy direction, in recent years, multiple policies in China have been continuously promoting the development of the brain-computer interface industry. The national "15th Five-Year Plan" also lists brain-computer interfaces as one of the six major future industries. Among local policies, Shanghai's "Action Plan for Cultivating the Future Industry of Brain-Computer Interfaces (2025-2030)" clearly proposes to promote more than 5 invasive and semi-invasive products to complete clinical trials by 2027.

With policy support, many domestic medical device companies have also entered the field, such as Boruikang, Brainpower, and Zhiran Medical. Boruikang's core product, NEO, is a semi-invasive product, while Brainpower focuses on the non-invasive track. Both companies launched their IPOs in February, aiming to become the first listed brain-computer interface company in China.

Meanwhile, ZhiRan Medical recently completed an A+ round of financing, bringing its total financing to 600 million yuan in just six months through two rounds. In 2025, ZhiRan Medical completed the first clinical implantation of a brain-computer interface product with over 100 channels in China. In 2026, it is expected to initiate large-scale registration clinical trials for its over 100-channel invasive brain-computer interface product.

https://news.yaozh.com/archive/47388.html